Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.

Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.

View in: PubMed

subject areas

Anticholesteremic Agents
Atherosclerosis
Cholesterol Ester Transfer Proteins
Cholesterol, HDL
Cholesterol, LDL
Double-Blind Method
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Lipoprotein(a)
Male
Middle Aged

authors with profiles

Michael H. Davidson